Transcriptional gene silencing by hypermethylation of CpG islands spanning the promoter regions of genes is a common and important mechanism in carcinogenesis. Hypermethylation leads to inactivation of gene expression, and this epigenetic alteration is considered a key mechanism for long-term gene silencing. Despite of thousands of reports in the literature describing hypermethylation of specific genes in almost every type of human cancer, the mechanisms of CpG island hypermethylation have remained obscure. This application will focus on mechanistic studies that will investigate the molecular pathways leading to DNA methylation changes in tumors with emphasis on DNA hypermethylation. As a key technology to accomplish these goals, we have recently developed a method that enables the precise genome-wide analysis of DNA cytosine methylation patterns in mammalian DNA. Using genome-wide methylation profiling, we will analyze the extent by which chemical carcinogens can induce DNA methylation changes. Using cell culture models, we will expose non-transformed human cells (fibroblasts, bronchial epithelial cells and mammary epithelial cells) to several chemical carcinogens. We will analyze DNA methylation changes within 27,800 CpG islands and along the entire short arms of chromosomes 3, 7, and 9. DNA methylation changes will be analyzed in a mouse skin carcinogenesis model in order to determine if epigenetic changes arise during the initiation or promotion of stages of carcinogenesis. We will also analyze if the same carcinogens can induce changes in histone modification patterns that may subsequently predispose the CpG islands to de novo DNA methylation. In another Specific Aim, we will analyze the hypothesis that DNA methylation changes can be induced by endogenous mechanisms including inflammation and oxidative DNA damage. We will investigate inflammation-induced DNA methylation changes using a mouse model in which inflammation is associated with cancer susceptibility. It has been hypothesized that the Polycomb repression complex present in stem cells at specific gene loci accelerates or facilitates recruitment of DNA methyltransferases and de novo methylation of CpG-rich sequences during the process of cell transformation. We will test this hypothesis using a neural stem cell and brain tumor model, which includes neural stem cells, stem cell-like glioma cells, and DNA samples from glioma tumors. Finally, the connection between Ras transformation, the Polycomb complex and DNA hypermethylation will be analyzed. NIH3T3 cells and immortalized epithelial cells will be transformed with the activated K-ras oncogene. We will determine if K-ras-induced transformation operates through the Polycomb complex to promote de novo methylation of CpG islands.
Despite of thousands of reports in the literature describing hypermethylation of specific genes in almost every type of human cancer, the mechanisms of tumor-associated CpG island hypermethylation have remained obscure. This application will focus on mechanistic studies that will investigate the molecular pathways leading to DNA methylation changes in tumors with emphasis on DNA hypermethylation. We will investigate if chemical carcinogens, or endogenous processes such as inflammation and oxidative stress can induce changes in DNA methylation. In parallel, we will study molecular pathways involving the Polycomb repression complex that might operate during tumor progression to promote hypermethylation of CpG islands in malignant tissue.
|Hahn, Maria A; Li, Arthur X; Wu, Xiwei et al. (2014) Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors. Cancer Res 74:3617-29|
|Rauch, Tibor A; Wang, Zunde; Wu, Xiwei et al. (2012) DNA methylation biomarkers for lung cancer. Tumour Biol 33:287-96|
|Hahn, Maria A; Wu, Xiwei; Li, Arthur X et al. (2011) Relationship between gene body DNA methylation and intragenic H3K9me3 and H3K36me3 chromatin marks. PLoS One 6:e18844|
|Jin, Seung-Gi; Wu, Xiwei; Li, Arthur X et al. (2011) Genomic mapping of 5-hydroxymethylcytosine in the human brain. Nucleic Acids Res 39:5015-24|
|Zheng, Li; Dai, Huifang; Hegde, Muralidhar L et al. (2011) Fen1 mutations that specifically disrupt its interaction with PCNA cause aneuploidy-associated cancer. Cell Res 21:1052-67|
|Jin, Seung-Gi; Jiang, Yong; Qiu, Runxiang et al. (2011) 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 71:7360-5|
|Besaratinia, Ahmad; Pfeifer, Gerd P (2010) Applications of the human p53 knock-in (Hupki) mouse model for human carcinogen testing. FASEB J 24:2612-9|
|Kim, Sang-In; Hollstein, Monica; Pfeifer, Gerd P et al. (2010) Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome. Mol Carcinog 49:999-1006|
|Wu, Xiwei; Rauch, Tibor A; Zhong, Xueyan et al. (2010) CpG island hypermethylation in human astrocytomas. Cancer Res 70:2718-27|
|Hahn, Maria A; Pfeifer, Gerd P (2010) Methods for genome-wide analysis of DNA methylation in intestinal tumors. Mutat Res 693:77-83|
Showing the most recent 10 out of 47 publications